Treatment that combines chemotherapy with radiotherapy.
Combined chemotherapy and radiotherapy given to augment some other form of treatment such as surgery. It is commonly used in the therapy of cancer.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Tumors or cancer of the ESOPHAGUS.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Tumors or cancer of the RECTUM.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Excision of part (partial) or all (total) of the esophagus. (Dorland, 28th ed)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A malignant epithelial tumor with a glandular organization.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.
Tumors or cancer of the NASOPHARYNX.
Antimetabolites that are useful in cancer chemotherapy.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the HYPOPHARYNX.
Tumors or cancer of the LUNG.
Techniques, procedures, and therapies carried out on diseased organs in such a way to avoid complete removal of the organ and preserve the remaining organ function.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
An organoplatinum compound that possesses antineoplastic activity.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.
Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.
Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.
Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed)
Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Tumors or cancer of the OROPHARYNX.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Surgery performed on the digestive system or its parts.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Organic compounds which contain platinum as an integral part of the molecule.
A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.
The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice.
Therapeutic act or process that initiates a response to a complete or partial remission level.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
Tumors or cancer of the UTERINE CERVIX.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tumors or cancer of the ANAL CANAL.
Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed)
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
Antagonist of urate oxidase.
CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.
INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
A general concept for tumors or cancer of any part of the EAR; the NOSE; the THROAT; and the PHARYNX. It is used when there is no specific heading.
Elements of limited time intervals, contributing to particular results or situations.
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
Total or partial excision of the larynx.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Tumors or cancer of the pelvic region.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A tubular organ of VOICE production. It is located in the anterior neck, superior to the TRACHEA and inferior to the tongue and HYOID BONE.
Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
External or interstitial irradiation to treat lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphomas) and lymph node metastases and also some autoimmune diseases, such as rheumatoid arthritis.
The excision of lung tissue including partial or total lung lobectomy.
Tumors or cancer of the STOMACH.
Pathological processes that affect voice production, usually involving VOCAL CORDS and the LARYNGEAL MUCOSA. Voice disorders can be caused by organic (anatomical), or functional (emotional or psychological) factors leading to DYSPHONIA; APHONIA; and defects in VOICE QUALITY, loudness, and pitch.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Tumors or cancer of the human BREAST.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Transplantation of an individual's own tissue from one site to another site.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Tumors or cancer of the PHARYNX.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Used for excision of the urinary bladder.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Spasmodic contraction of the masseter muscle resulting in forceful jaw closure. This may be seen with a variety of diseases, including TETANUS, as a complication of radiation therapy, trauma, or in association with neoplastic conditions.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
The vocal apparatus of the larynx, situated in the middle section of the larynx. Glottis consists of the VOCAL FOLDS and an opening (rima glottidis) between the folds.
Tumors or cancer of the NOSE.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
The return of a sign, symptom, or disease after a remission.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
The use of combination of imaging techniques or platforms (e.g., MRI SCAN and PET SCAN) encompassing aspects of anatomical, functional, or molecular imaging methods.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
The period following a surgical operation.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Surgical removal of a part of the pharynx. (Dorland, 28th ed)
The study of chance processes or the relative frequency characterizing a chance process.
The act of taking solids and liquids into the GASTROINTESTINAL TRACT through the mouth and throat.
The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Delivery of medications through the nasal mucosa.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Antibodies produced by a single clone of cells.
Dissection in the neck to remove all disease tissues including cervical LYMPH NODES and to leave an adequate margin of normal tissue. This type of surgery is usually used in tumors or cervical metastases in the head and neck. The prototype of neck dissection is the radical neck dissection described by Crile in 1906.
Tumors or cancer of the URINARY BLADDER.
A subspecialty of internal medicine concerned with the study of neoplasms.
Abnormal passage communicating with the ESOPHAGUS. The most common type is TRACHEOESOPHAGEAL FISTULA between the esophagus and the TRACHEA.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A subspecialty of medical oncology and radiology concerned with the radiotherapy of cancer.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
ARTHRITIS that is induced in experimental animals. Immunological methods and infectious agents can be used to develop experimental arthritis models. These methods include injections of stimulators of the immune response, such as an adjuvant (ADJUVANTS, IMMUNOLOGIC) or COLLAGEN.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A decrease in the number of NEUTROPHILS found in the blood.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Tumors or cancer of the MOUTH.
Surgical incision into the chest wall.
Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The act of dilating.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES.
A subnormal level of BLOOD PLATELETS.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.
Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.
The period before a surgical operation.
An enzyme of the transferase class that catalyzes the reaction 5,10-methylenetetrahydrofolate and dUMP to dihydrofolate and dTMP in the synthesis of thymidine triphosphate. (From Dorland, 27th ed) EC 2.1.1.45.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.

The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. (1/158)

 (+info)

Long-term toxic effects of adjuvant chemotherapy in breast cancer. (2/158)

 (+info)

Elevation in exhaled nitric oxide predicts for radiation pneumonitis. (3/158)

 (+info)

Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement? (4/158)

 (+info)

Lymphoepithelial carcinoma: two case reports and a systematic review of oral and sinonasal cases. (5/158)

 (+info)

Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (6/158)

Strong evidence exists for the use of adjuvant chemotherapy following surgical resection in pancreatic cancer, whereas the role of adjuvant chemoradiotherapy remains controversial. The optimal time to initiate adjuvant therapy has yet to be elucidated, but is usually started 2-10 weeks following resection. First line adjuvant chemotherapy is gemcitabine, as this drug has demonstrated the better efficacy in studies. Other chemotherapeutic agents and gemcitabine in combination with biologic agents are under investigation. Furthermore, predicting response to gemcitabine based chemotherapy and other adjuvant therapies will be invaluable in guiding the practitioner to choose the most appropriate adjuvant treatment. Once adjuvant therapy has been started, accurately quantifying response to therapy is also important. The adjuvant regimen may be appropriately modified if response is inadequate. This review is an update from the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding recent developments in the adjuvant treatment of pancreatic cancer with regards to choice of adjuvant regimen, timing of adjuvant therapy, predicting response to therapy and measuring response to adjuvant therapy. We will present the findings from Abstracts #4039, #4042, #e14519, #4118, and #4024. In conclusion, multiple adjuvant therapeutic regimens are associated with incremental improvements in the management of pancreatic cancer. The timing of initiation of adjuvant therapy appears to be important in outcomes. Research is ongoing into markers that can predict response to adjuvant therapy.  (+info)

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. (7/158)

 (+info)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). (8/158)

 (+info)

Bladder-preserving trimodal therapy is recognized as a promising alternative treatment for muscle-invasive bladder cancer. We report the updated outcomes of muscle-invasive bladder cancer patients that were treated using our treatment protocol, which involves radiotherapy delivered with a real-time tumor-tracking radiotherapy system.
Muscle degeneration has been consistently identified as an independent risk factor for high mortality in both aging populations and individuals suffering from neuromuscular pathology or injury. While there is much extant literature on its quantification and correlation to comorbidities, a quantitative gold standard for analyses in this regard remains undefined. Herein, we hypothesize that rigorously quantifying entire radiodensitometric distributions elicits more muscle quality information than average values reported in extant methods. This study reports the development and utility of a nonlinear trimodal regression analysis method utilized on radiodensitometric distributions of upper leg muscles from CT scans of a healthy young adult, a healthy elderly subject, and a spinal cord injury patient. The method was then employed with a THA cohort to assess pre- and postsurgical differences in their healthy and operative legs. Results from the initial representative models elicited high degrees of
However, as previously mentioned, it is the incongruent conditions that probe the statistical inference rules that the nervous system must use in resolving potential conflicts in sensory cues. In incongruent conditions, there are often considerable deviations from the veridical response in one or more of the modalities. In other words, the information in the task-irrelevant one or two modalities affects the response distribution in the task-relevant modality. However, not all differences between two response distributions necessarily reflect meaningful interactions between modalities, as they may be due to sampling error. For example, the change in the visual response between unimodal condition [ V = 1, A = 0, T = 0] and bimodal condition [ V = 1, A = 2, T = 0] may be either statistically insignificant or could correspond to a statistically significant modulation of visual perception by sound. Therefore, to find which of the changes between two conditions correspond to a statistically ...
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method. It remains uncertain whether patients with resectable EC can benefit from neoadjuvant chemoradiotherapy.. A research article to be published on December 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team from China selected eleven randomized controlled trials (RCTs) including 1308 patients. The reuslts showed neoadjuvant chemoradiotherapy significantly improved the overall survival compared with surgery alone. Histological subgroup analysis indicated that esophageal squamous cell carcinoma did not benefit from neoadjuvant chemoradiotherapy.. Their meta-analysis suggest that patients ...
To evaluate the benefit of adjuvant treatments, such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB) cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n = 59, 39.1%) or CTx (n = 39, 25.8%), and the remaining 53 (35.1%) did not (No-AT). The clinicopathological factors, patterns of failure, locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS) and overall survival (OS) were compared among the three groups according to tumor stage. In patients with T2-3N0M0 stage disease, the incidences of locoregional recurrence and distant recurrence and 5-year LRFS, RFS and OS rates were not significantly different among the No-AT, CTx, and CRT groups (p | 0.05 each). In those with T2-3N1-2M0 stage disease, the incidences of locoregional recurrence (11.4%, 78.1%, and 68.4%, respectively) and distant recurrence (42.8%, 73.9% and 66.7%, respectively) in the CRT group were
The likelihood of a tumor recurrence in patients with T3-4N0-1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens are seen in only a minority (28-38%) of patients following chemoradiotherapy, we designed the INCREASE trial (EudraCT-Number: 2019-003454-83; Netherlands Trial Register number: NL8435) to assess if pCR rates could be further improved by adding short course immunotherapy to induction chemoradiotherapy. Translational studies will correlate changes in loco-regional and systemic immune status with patterns of recurrence. This single-arm, prospective phase II trial will enroll 29 patients with either resectable, or borderline resectable, T3-4N0-1 NSCLC. The protocol was approved by the institutional ethics committee. Study enrollment commenced in February 2020. On day 1 of guideline-recommended concurrent chemoradiotherapy (CRT), ipilimumab (IPI, 1 mg/kg IV) and nivolumab
Oesophageal adenocarcinoma (OAC) is the sixth most common cause of cancer deaths worldwide, and the 5-year survival rate for patients diagnosed with the disease is approximately 17%. The standard of care for locally advanced disease is neoadjuvant chemotherapy or, more commonly, combined neoadjuvant chemoradiation therapy (neo-CRT) prior to surgery. Unfortunately, ~60-70% of patients will fail to respond to neo-CRT. Therefore, the identification of biomarkers indicative of patient response to treatment has significant clinical implications in the stratification of patient treatment. Furthermore, understanding the molecular mechanisms underpinning tumour response and resistance to neo-CRT will contribute towards the identification of novel therapeutic targets for enhancing OAC sensitivity to CRT. MicroRNAs (miRNA/miR) function to regulate gene and protein expression and play a causal role in cancer development and progression. MiRNAs have also been identified as modulators of key cellular ...
BackgroundTo evaluate the value of pretreatment inflammatory-nutritional biomarkers in predicting responses to neoadjuvant chemoradiotherapy (nCRT) and survival in patients with locally advanced rectal cancer (LARC).MethodsPatients with LARC who underwent nCRT and subsequent surgery between October 2012 and December 2019 were considered for inclusion. Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), and prognostic nutritional index (PNI) were calculated from according to routine laboratory data within 1 week prior to nCRT. The correlations between baseline inflammatory-nutritional biomarkers and responses were analyzed using Chi-square test or Fishers exact test, and multivariate logistic regression analysis was performed to identify the independent predictors of pathological responses to nCRT. Univariate and multivariate Cox proportional hazard models were used to assess the correlations of predictors with disease-free survival (DFS) and
In this segment, Tanios Bekaii-Saab, MD, FACP; Johanna C. Bendell, MD; Ramesh K. Ramanathan, MD; and Thomas Seufferlein, MD, review their protocols for treating borderline resectable pancreas cancer and considerations in making decisions about the appropriateness for recommending surgery after chemotherapy.
A B S T R AC T BACKGROUND The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well
Noordman, B.J.; Spaander, M.C.W.; Valkema, R.; Wijnhoven, B.P.; Berge Henegouwen, M.I. van; Shapiro, J.; Siersema, P.D.; Janssen, M.J.R.; Post, R.S. van der; Radema, S.A.; Rosman, C. ; Rütten, H.; Lanschot, J.J. van; Steyerberg, E.W. ...
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
NewLink Genetics (NASDAQ: NLNK) announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable ...
Findings from a recent study demonstrate that the PD-L1 inhibitor durvalumab demonstrated statistically significant and clinically meaningful improvement in
Neoadjuvant radiochemotherapy has been proven superior to adjuvant treatment in reducing the rate of local recurrence without impairing cancer related survival or the incidence of distant metastases in standard protocols of neoadjuvant radiochemotherapy. The present study aimed at addressing the effects of an intensified neoadjuvant radiochemotherapy on long term cancer related and disease free survival. A total of 387 patients underwent oncologic resection for rectal cancer in our institution between January 2000 and December 2009. There were 106 patients (27.4%) who received an intensified radiochemotherapy protocol completely and without excluding criteria (study group). A matched pair analysis was performed by comparing the study group with patients undergoing primary surgery and postoperative radiochemotherapy, if necessary and possible (control group). Matching was carried out in descending order for UICC stage, R-status, tumor height, T-, N-, V-, L-, M- and G-category of the TNM-system according
An analysis in the Dutch Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study (CROSS) reported by Noordman et al in the Journal of Clinical Oncology showed no adverse effect of neoadjuvant chemoradiotherapy vs surgery alone on postsurgery health-related quality of life in patients with esophageal or esophagogastric junction cancer.. Study Details. The CROSS study showed significant improvement in overall survival with neoadjuvant chemoradiotherapy (carboplatin plus paclitaxel with concurrent 41.4-Gy radiotherapy) vs surgery alone. In the current analysis, health-related quality of life was assessed by the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (QLQ-C30) and -Oesophageal Cancer Module (QLQ-OES24) questionnaires prior to treatment and at 3, 6, 9, and 12 months after surgery; the neoadjuvant therapy group also received preoperative questionnaires. QLQ-C30 physical functioning and QLQ-OES24 eating problems were predefined primary ...
As a charity, Action Radiotherapy is entirely reliant on donations to support our work. We are extremely grateful to Varian for providing a charitable donation to support our radiotherapy news service. If you would like to receive a daily email with the latest radiotherapy news, please sign up here. ...
Rectal cancer is a frequent but curable malignancy in the Western world. The golden standard in treating these patients consists of neoadjuvant chemoradiotherapy (CRT) followed by extensive surgery regardless of tumor response. The main question is whether extensive surgery can be avoided holding in mind that already a significant amount of patients reach a pathological complete response after radiochemotherapy. The goal of this study is dual. First of all, the investigators want to investigate the value of DW-MRI and 18FDG-PET in the assessment of response after neoadjuvant CRT in 100 patients with rectal cancer, to select those patients eligible for less invasive surgery. In the same patient group, the investigators will examine the biomarker potential of molecular characteristics of the tumor in blood and tissue. Using both molecular and radiological findings, the investigators want to predict pathological response after chemoradiotherapy and to select patients who may benefit from treatment ...
Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters Academic Article ...
Locally advanced rectal cancer is regularly treated with trimodality therapy consisting of neoadjuvant chemoradiation, surgery and adjuvant chemotherapy. There is a need for biomarkers to assess treatment response, and aid in stratification of patient risk to adapt and personalise components of the therapy. Currently, pathological stage and tumour regression grade are used to assess response. Experimental markers include proteins involved in cell proliferation, apoptosis, angiogenesis, the epithelial to mesenchymal transition and microsatellite instability. As yet, no single marker is sufficiently robust to have clinical utility. Microarrays that screen a tumour for multiple promising candidate markers, gene expression and microRNA profiling will likely have higher yield and it is expected that a combination or panel of markers would prove most useful. Moving forward, utilising serial samples of circulating tumour cells or circulating nucleic acids can potentially allow us to demonstrate tumour
TY - JOUR. T1 - Current Concepts on the Distal Margin of Resection of Rectal Cancer Tumors after Neoadjuvant Chemoradiation. AU - Imran, Jonathan. AU - Yao, Jie J.. AU - Madni, Tarik. AU - Huerta, Sergio. PY - 2017/1/23. Y1 - 2017/1/23. N2 - Purpose of Review: The following review addresses concepts regarding the appropriate distal margin of resection for adenocarcinoma of the rectum in the era of preoperative chemoradiation. Recent Findings: The management of adenocarcinoma of the rectum continues to improve in all aspects of its tri-modality treatment (preoperative chemoradiation, surgery, and adjuvant therapy). The multidisciplinary approach to the management of this disease continues to evolve with a goal to provide better oncologic outcomes with less morbidity in patients affected by this disease. For locoregionally advanced disease, total mesorectal excision continues to be the standard of care for an intended cure for this cohort of patients. As we understand more regarding the oncologic ...
Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumours with dismal prognosis. Although curative resection with adjuvant chemoradiotherapy is the most effective treatment, the
Inclusion Criteria: - Histologically confirmed diagnosis of supratentorial WHO Grade III or IV Glioma (High Grade Glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and a stereotactic biopsy is indicated for confirmation of recurrence/progression. - 18 years of age or older - Karnofsky Performance Status 70-100; - MRI demonstration of a stereotactically accessible enhancing or predominantly non- enhancing mass that does not require resection to relieve clinically significant mass effect; - Participant understands the procedures and agrees to comply with the study requirements by providing written informed consent - Adequate organ function as indicated in protocol Exclusion Criteria: - Participant is mentally or legally incapacitated at the time of the study; - Known HIV(+) or has been diagnosed with AIDS - Participation in another investigational drug study in the prior 4 weeks - ...
Rectal cancer is a frequent but curable malignancy in the Western world. The golden standard in treating these patients consists of neoadjuvant chemorad
Abstract: Objective: To evaluate the clinical relevance of preoperative airway colonisation in patients undergoing oesophagectomy for cancer after a neoadjuvant chemoradiotherapy. Methods: From 1998 to 2005, 117 patients received neoadjuvant chemoradiotherapy for advanced stage oesophageal cancer. Among them, 45 non-randomised patients underwent a bronchoscopic bronchoalveolar lavage (BAL group) prior to surgery to assess airways colonisation. The remaining patients (n =72) constituted the control group. The two groups were similar with respect to various clinical or pathological characteristics. Results: Thirteen of the 45 BAL patients (28%) had a preoperative bronchial colonisation by either potentially pathogenic micro-organisms (PPMs) (n =7, 16%) or non-potentially pathogenic micro-organisms (n =6, 13%). Cytomegalovirus (CMV) was cultured from BAL in four patients. Pre-emptive therapy was administrated in seven patients: four antiviral and three antibiotic prophylaxes. Postoperatively, 14 ...
Offline two-dimensional chromatography is a common means to achieve deep proteome coverage. To reduce sample complexity and dynamic range and to utilize mass spectrometer (MS) time efficiently, high chromatographic resolution of and good orthogonality between the two dimensions is needed. Ion exchange and high pH reversed phase chromatography are often used for this purpose. However, the former requires desalting to be MS-compatible and the latter requires fraction pooling to create orthogonality. Here, we report an alternative first-dimension separation technique using a commercial trimodal phase incorporating polar embedded reversed phase, weak anion exchange and strong cation exchange material. The column is capable of retaining polar and nonpolar peptides alike without noticeable breakthrough. It allows separating ordinary and TMT-labelled peptides under mild acidic conditions using an acetonitrile gradient. The direct MS compatibility of solvents and good orthogonality to online coupled C18 ...
Offline two-dimensional chromatography is a common means to achieve deep proteome coverage. To reduce sample complexity and dynamic range and to utilize mass spectrometer (MS) time efficiently, high chromatographic resolution of and good orthogonality between the two dimensions is needed. Ion exchange and high pH reversed phase chromatography are often used for this purpose. However, the former requires desalting to be MS-compatible and the latter requires fraction pooling to create orthogonality. Here, we report an alternative first-dimension separation technique using a commercial trimodal phase incorporating polar embedded reversed phase, weak anion exchange and strong cation exchange material. The column is capable of retaining polar and nonpolar peptides alike without noticeable breakthrough. It allows separating ordinary and TMT-labelled peptides under mild acidic conditions using an acetonitrile gradient. The direct MS compatibility of solvents and good orthogonality to online coupled C18 ...
TY - JOUR. T1 - A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. AU - Nikas, Jason B.. AU - Lee, Janet T.. AU - Maring, Elizabeth D.. AU - Washechek-Aletto, Jill. AU - Felmlee-Devine, Donna. AU - Johnson, Ruth A.. AU - Smyrk, Thomas C.. AU - Tawadros, Patrick S.. AU - Boardman, Lisa A.. AU - Steer, Clifford J. PY - 2015/1/1. Y1 - 2015/1/1. N2 - An important determinant of the pathogenesis and prognosis of various diseases is inherited genetic variation. Single-nucleotide polymorphisms (SNPs), variations at a single base position, have been identified in both protein-coding and noncoding DNA sequences, but the vast majority of millions of those variants are far from being functionally understood. Here we show that a common variant in the gene MTHFR [rs1801133 (C,T)] not only influences response to neoadjuvant chemoradiotherapy in patients with rectal cancer, but it also influences recurrence of the disease itself. More specifically, patients with ...
This trial will assess the efficacy and tolerability of neoadjuvant chemoradiotherapy with bevacizumab + oxaliplatin + fluorouracil in patients with locall
Preoperative chemoradiation leads to increased pelvic control and overall survival, but both distant and local disease control remain problematic in loc
Patients with rectal cancer reported aerobic exercise during neoadjuvant chemoradiotherapy to be more enjoyable and less difficult.
Increasing the Rates of Complete Response to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer: Results of a Prospective Study Using Additional Chemotherap
Admixture analysis of age at onset (AAO) has helped delineating the clinical profile of early onset (EO) bipolar disorder (BD). However, there is scarce evidence comparing the distributional properties of AAO as well as the clinical features of EO BD type 1 (BD1) with EO BD type 2 (BD2). To this end, we studied 515 BD patients (224 BD1, 279 BD2, and 12 BD not otherwise specified [NOS]) diagnosed according to DSM-IV-TR criteria. AAO was defined as the first reliably diagnosed hypo/manic or depressive episode according to diagnostic criteria. We used normal distribution mixture analysis to identify subgroups of patients according to AAO. Models were chosen according to the Schwarzs Bayesian information criteria (BIC). Clinical correlates of EO were analysed using univariate tests and multivariate logistic regression models. A two normal components model best fitted the observed distribution of AAO in BD1 (BIC = −1599.3), BD2 (BIC = −2158.4), and in the whole sample (BIC = −3854.9). A higher number
The preparation of a branched, radial block copolymer having improved falling weight impact properties, and having trimodal distribution of molecular structure in the arms of the block copolymer is described.
TY - JOUR. T1 - Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer. T2 - A meta-analytical evaluation of prospective studies. AU - Festa, Virginia. AU - Andriulli, Angelo. AU - Valvano, Maria Rosaria. AU - Uomo, Generoso. AU - Perri, Francesco. AU - Andriulli, Nicola. AU - Corrao, Salvatore. AU - Koch, Maurizio. PY - 2013. Y1 - 2013. N2 - Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therapy remains to be defined. Objective We did a systematic search of the literature on this topic. Methods Prospective studies where chemotherapy with or without radiotherapy was given before surgery to patients with borderline resectable cancer, were analyzed by a metaanalytical approach. Main outcome measures Primary outcome was surgical exploration and resection rates; tumor response, therapy-induced toxicity, and survival were secondary outcomes. Data were expressed as weighted pooled proportions with 95% confidence intervals ...
Dr. Rebeccah Baucom of Vanderbilt University in Nashville, Tennessee and colleagues presented the results of the study June 11 at the 2017 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Seattle, Washington.. Patients who have rectal cancer with clinical nodal disease, high-grade tumors, or tumors with perineural or lymphovascular invasion should undergo total mesorectal excison regardless of their tumor response to neoadjuvant radiation, said senior author Dr. Alexander T. Hawkins of Vanderbilt University.. The findings showed that more aggressive tumors, based on histology and stage, do not respond as well to neoadjuvant chemoradiation therapy, he told Reuters Health by phone.. In a relatively new treatment modality for patients with rectal cancer called watch and wait, patients undergo neoadjuvant chemoradiation therapy, it looks like their tumor goes away, and they can be observed rather than undergo surgery, Dr. Hawkins explained. Our findings are very ...
Background: The accuracy of restaging in patients with stage IIIa non-small cell lung cancer after neoadjuvant chemoradiotherapy is unknown. Methods: A prospective trial of patients with biopsy-proven N2 disease who underwent initial clinical staging with mediastinoscopy, integrated positron emission tomography/computed tomography (PET/CT), and CT. Patients then were clinically restaged by the same imaging techniques 4 to 12 weeks after their induction chemoradiation therapy and then underwent definitive pathologic staging. Results: Ninety-three patients had their lymph nodes pathologically restaged. Repeat PET/CT after neoadjuvant therapy missed residual N2 disease in 13/65 (20%) patients and falsely suggested it in 7 of 28 (25%). It was more accurate than repeat CT for restaging at all pathologic stages (stage 0, 92% vs 39%, P = .03; and stage I 89% vs 36%, P = .04). When the maximum standardized uptake value of the primary tumor is decreased by 75% or more, it is highly likely (likelihood ...
TY - JOUR. T1 - Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. AU - Cheng, Tsung Yen. AU - Sheth, Ketan. AU - White, Rebekah R.. AU - Ueno, Tomio. AU - Hung, Cheng Fang. AU - Clary, Bryan M.. AU - Pappas, Theodore N.. AU - Tyler, Douglas S.. PY - 2006/1/1. Y1 - 2006/1/1. N2 - Background: Neoadjuvant chemoradiotherapy (neo-CRT) is being used with increasing frequency for periampullary tumors, but how it alters the complication rate of pancreaticoduodenectomy (PD) is unclear. Methods: A retrospective analysis was conducted of 79 patients with periampullary malignancies who received 5-fluorouracil-based neo-CRT followed by PD. Results: There was no difference in mortality between PD after neo-CRT (3.8%) and conventional PD for either malignant (4.5%) or benign (2.2%) disease. Focusing only on patients with malignancy, the neo-CRT group had a significantly lower pancreatic leak rate than the conventional group (10% vs. 43%; P , .001). ...
Background In the United Kingdom, patients with locally advanced rectal cancer routinely receive neoadjuvant chemoradiotherapy. capacity muscle mitochondrial function raises the possibility that muscle mitochondrial mechanisms, no doubt multifactorial, may be important in deterioration of physical fitness following neoadjuvant chemoradiotherapy. This may have implications for targeted interventions to improve physical fitness pre-surgery. Trial Registration Clinicaltrials.gov registration type:clinical-trial,attrs:text:NCT01859442″,term_id:NCT01859442″NCT01859442 Introduction In the UK colorectal cancer is the third commonest cause of cancer death [1], [2]. In 2013, 9000 patients were diagnosed with rectal cancer (35% aged >75 y), of whom 4600 underwent major resection with a 90-day elective postoperative mortality of 2.5% [3]. 25% are locally advanced (Tumour, Node, Metastasis (TNM) stage - T3/T4N+) cancers (i.e. resection margin threatened) considered for neoadjuvant ...
Background Patients with locally advanced rectal cancer receive neoadjuvant chemoradiation therapy (CRT) and subsequent surgery. While 10-25% of patients have complete response to CRT, the remaining patients undergo extensive tumor excision resulting in significant quality of life issues. Response to CRT is an independent predictor of overall survival highlighting the importance of improving CRT response rates. Several tumor intrinsic factors govern responses to CRT including specific gene expression programs. Emerging evidence suggests that microRNAs (miRs) modulate gene expression programs in response to radiation and have been implicated in several pathological processes associated with colorectal cancer progression. In this context, we hypothesized that differential expression of miRs regulates colorectal cancer radiation sensitivity and can be used as a biomarker to predict radiation efficacy.. Methods To investigate the differences in miR profiles between rectal cancer patients that had ...
[Over the last several decades, local control (LC) for rectal cancer has markedly improved because of advances in surgical technique and the adoption of adjuvant or neoadjuvant chemoradiotherapy (CRT). Total mesorectal excision (TME) during surgical resection of localized rectal cancer, which involves removal of the entire circumferential perirectal tissue envelope, decreases rates of both involved surgical margins and local recurrences. Similarly, for patients with locally advanced rectal cancer (LARC), including T3 and T4 tumors and lymph node-positive disease, adjuvant and more preferably neoadjuvant CRT has exhibited the ability to both improve disease-free survival (DFS) and LC. Some patients undergoing neoadjuvant CRT achieve a complete pathologic response (pCR) to CRT and the oncologic outcomes are particularly favourable in this group. In contrast to improved local control, patients overall survival rates are in need of improvement, and the major factor limiting the outcome is the appearance of
BACKGROUND: There are no reports available on the long-term outcome of patients with the liver first approach. OBJECTIVES: The aim of this study was to present the long-term results of the liver first approach in our center. DESIGN: This study is a retrospective analysis. SETTING: This study was conducted at a tertiary referral center. PATIENTS: Patients from May 2003 to March 2009 were included. INTERVENTIONS: Patients with locally advanced rectal cancer and synchronous liver metastases were first treated for their liver metastases. If the treatment was successful, patients underwent neoadjuvant chemoradiotherapy and surgery for the rectal cancer. If metastases could not be resected, resection of the rectal primary was not routinely performed. MAIN OUTCOME MEASURES: The primary outcome measured was long-term results of the liver first approach. RESULTS: Of the 42 patients included (median age, 61 years), all but one (98%) started with neoadjuvant chemotherapy. In total, 31 (74%) patients ...
Introduction: Fluorouracil (5-FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5-FU thymidylate synthase (TS) is a promising biomarker in rectal[for full text, please go to the a.m. URL ...
ZnO-containing MFI zeolite catalysts with bimodal and trimodal hierarchical pore structures were prepared, characterized and studied for the conversion of methanol to aromatics. Treatments of H-ZSM-5 with NH4F and NaOH generated bigger micropores with a mean size of around 0.8 nm and mesopores with mean size
Rectal cancer management is becoming increasingly complex. There is increasing recognition of the potential to avoid routine chemoradiotherapy, as excellent results can be achieved with a more selective approach.
In an observational study reported in JAMA Oncology, Kelly et al found that overall survival was similar with upfront surgery and definitive chemoradiotherapy among patients with newly diagnosed cT1-2 N1-2b human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma.. Study Details. The study involved 1,044 patients from the National Cancer Database who were newly diagnosed between 2010 and 2012. Among them, 460 patients (44.1%) received upfront surgery, and 584 patients (55.9%) received chemoradiotherapy. Median age was 59 years (range, 25-90 years), and 77.8% were male. Adjuvant chemoradiotherapy was received by 59% of surgical patients.. Survival Outcomes. Median follow-up was 30 months. Overall, 3-year overall survival was 81.4% in the surgery group vs 79.2% in the chemoradiotherapy group (P = .65). On multivariable analysis, the adjusted hazard ratio for death for surgery vs chemoradiotherapy was 1.01 (P = .93). In a propensity score-matched cohort of 822 patients, the hazard ...
The purpose of the present study was to investigate risk factors associated with local recurrence in patients with locally advanced rectal cancer who received preoperative chemoradiotherapy in combination with total mesorectal excision (TME). Rectal cancer patients who were treated with neoadjuvant chemoradiation with TME were studied. We compared 26 patients who developed local recurrence with 119 recurrence-free patients during the follow-up period. The median follow-up period was 52 months (range: 14â€131 months). Based on the use of univariate and multivariate analyses, circumferential margin involvement ( p = 0.02), the presence of lymphovascular or perineural invasion ( p = 0.02), and positive nodal disease ( p = 0.03) were contributing factors for local recurrence. The local recurrence rate was different between ypN(+) patients and ypN(â€) patients with more than 12 nodes retrieved ( p = 0.01). There was no difference in local recurrence rates between ypN(+) patients and ...
microRNAs (miRNAs) are small non-coding RNAs with important post-transcriptional regulatory functions. miRNA-21 (miR-21) is upregulated and miR-143 and miR-145 are downregulated in colorectal carcinoma. The aim of our study was to determine if these miRNAs change their expression levels in response to neoadjuvant chemoradiotherapy in advanced rectal cancer. Forty patients with advanced rectal cancer (clinical uT3/T4 Nx) were included. All patients underwent neoadjuvant chemoradiotherapy and surgical resection. Expression of miR-21, -143 and -145 was examined in macrodissected tumor tissue before and after chemoradiotherapy and normal rectal tissue from the resection specimen. RNA was extracted from formalin-fixed and paraffin-embedded tissue by TRIzol method, polyadenylated, reverse transcribed and analyzed by real-time PCR. Therapy response was assessed according to pathological tumor regression. miR-21 was more highly expressed in tumor tissue than in non-tumorous tissue. However, there was a ...
OBJECTIVES: We aimed to examine the association between total number of resected nodes and survival in patients after esophagectomy with and without nCRT. BACKGROUND: Most studies concerning the potentially positive effect of extended lymphadenectomy on survival have been performed in patients who underwent surgery alone. As nCRT is known to frequently sterilize regional nodes, it is unclear whether extended lymphadenectomy after nCRT is still useful. METHODS: Patients from the randomized CROSS-trial who completed the entire protocol (ie, surgery alone or chemoradiotherapy + surgery) were included. With Cox regression models, we compared the impact of number of resected nodes as well as resected positive nodes on survival in both groups. RESULTS: One hundred sixty-one patients underwent surgery alone, and 159 patients received multimodality treatment. The median (interquartile range) number of resected nodes was 18 (12-27) and 14 (9-21), with 2 (1-6) and 0 (0-1) resected positive nodes, ...
We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC). This retrospective study investigated the clinicopathological features and | 5-year survival of patients with T3/T4 PDAC who underwent NACRT at our institute between 2003 and 2012. Seventeen resectable and eight borderline resectable patients were included. The protocol treatment completion and resection rates were 92.0% and 68.0%, respectively. Two patients failed to complete chemotherapy owing to cholangitis or anorexia. Common grade 3 toxicities included anorexia (12%), neutropenia (4%), thrombocytopenia (4%), anemia (4%), and leukopenia (12%). Pathologically negative margins were achieved in 94.1% of patients who underwent pancreatectomy. Pathological response according to Evans classification was grade IIA in 10 patients (58.8%), IIB in 5 patients (29.4%), and IV in 2 patients (11.8%). Postoperative
The researchers identified 6 eligible randomized controlled trials. The team found that chemoradiotherapy plus surgery, compared with surgery alone, significantly reduced the 3 year mortality rate (odds ratio 0.53). They also found that preoperative chemoradiotherapy downstaged the tumor. However, the risk for postoperative mortality was higher in the chemoradiotherapy plus surgery group (odds ratio 2.10). Dr Fiorica and colleagues concluded, In patients with resectable esophageal cancer, chemoradiotherapy plus surgery significantly reduces 3 year mortality compared with surgery alone . However, postoperative mortality was significantly increased by neoadjuvant chemoradiotherapy . Further large scale multicenter randomized controlled trials may prove useful to substantiate the benefit on overall survival . ...
Our study showed that obesity is a critical prognostic factor for LC in rectal cancer. The strategy of improving LC in these patients could bring about a better outcome.. Obesity affects not only surgical complications but also treatment outcomes in rectal cancer patients [19]. Clark et al. [20] reported that elevated visceral adiposity was associated with an increased risk of recurrence after neoadjuvant chemoradiation in rectal cancer. Our results bolster this view. For local treatment, sufficient resection of the tumor might be difficult in obese patients because of limited surgical visibility. In addition, increased set-up uncertainty during RT in obese patients might influence the treatment results. Personalized RT may improve the LC rate in obese patients. An increase in the boost dose of RT in obese rectal cancer patients should be considered to reduce local failure. Intensive systemic treatment and active secondary prevention can also reduce the risk of local recurrence in obese ...
The prognosis of esophageal cancer is poor as most patients present with locally advanced or metastatic disease. The treatment of choice in patients with locally advanced disease (T2-4a/N1-3/M0) is radical surgery with neoadjuvant chemoradiation. Nevertheless, even after neoadjuvant chemoradiation, recurrences occur frequently and complete responses are still relatively low. The response rate of neoadjuvant treatment (41.4 Gy with concurrent carboplatin/paclitaxel) varies between 22%-35%. Another problem is the high rate of recurrences (up to 50%), even after a pathologic complete response (pCR). To gain more insight in the cause of the relatively low response rate and recurrences after pCR, we need to obtain a better understanding of the nature of these tumors and determine better predictive factors. A population of cells the so-called cancer stem-like cells (CSCs) is known to be highly resistant to chemoradiation and therefore targeting these cells might contribute to a better response. With ...
BACKGROUND We systematically reviewed and performed a meta-analysis of the available data regarding neoadjuvant chemo- and/or radiotherapy with special emphasis on tumor response/progression rates, toxicities, and clinical benefit, i.e. resection probabilities and survival estimates. METHODS AND FINDINGS Trials were identified by searching PUBMED, MEDLINE, and the Cochrane Central Register of Controlled Trials from 1966 to Feb 2015. A total of 18 studies (n = 959) were analyzed. the estimated fraction of patients with complete response was 2.8% (CI 0.8-4.7%) and with partial response 28.7% (CI 18.9%-38.5%). Stable disease was averaged to 45.9% (CI 32.9%-58.9%) in all patients and tumor progression under therapy occurred by estimation in 16.9% (CI 10.2%-23.6%) of the patients. The weighted frequency of those who underwent resection was 65.3% (CI 54.2%-76.5%), and the proportion of R0 resection amounted to 57.4% (CI 48.2%-66.5%). The weighted mean of median survival amounted to 17.9 months (range: 14.7
BACKGROUND: The aim of the study was to evaluate the added value of the apparent diffusion coefficient (ADC) of diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with rectal cancer who received neoadjuvant chemoradiotherapy (CRT). The use of DW-MRI for response evaluation in rectal cancer still remains a widely investigated issue, as the accurate detection of pathologic complete response (pCR) is critical in making therapeutic decisions. PATIENTS AND METHODS: Thirty-three patients with locally advanced rectal cancer were evaluated retrospectively by MRI in addition to diffusion-weighted images (DWI) and its ADC pre- and post-neoadjuvant CRT ...
Fingerprint Dive into the research topics of Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Together they form a unique fingerprint. ...
Neoadjuvant chemoradiotherapy did not improve resection rates or survival outcomes in patients with early-stage, locally advanced esophageal cancer.
B71 Background: In locally advanced stages of rectal cancer preoperative combined modality treatment has become the standard therapeutical intervention. Efficacy of neoadjuvant chemoradiation is compromised in some patients by so far unknown factors. These patients could be saved from side effects and surgery could be scheduled without delay. The aim of the present study was to investigate topoisomerase I expression as a potential parameter for predicting tumor response to irinotecan in comparison to adjacent normal tissue.Methods: Twenty patients with rectal cancer clinical stages T3/4 Nx or N+ were recruited to receive weekly neoadjuvant irinotecan (1 hour before radiation) and capecitabine as well as cetuximab with a concurrent RT dose of 50.4 Gy (45+5.4 Gy).Surgery was scheduled 4-6 weeks after the completion of chemoradiation.Samples of normal and tumor tissues of all patients were collected before neoadjuvant treatment. Initially, RNA-oligonucleotid-array of six patients (three ...
CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study
An Absolute Standardized Uptake Value Is More Useful than the Decreased Rate of Uptake of FDG-PET to Predict Responses to Neoadjuvant Chemoradiotherapy for Esophageal Cancer. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Adjuvant therapy followed by liver transplantation may have a role in treatment of certain unresectable cases. Locoregional ... The role of combined chemoradiotherapy in this setting is unclear. However, if the tumor tissue margins are positive, ... If the tissue margins are negative (i.e. the tumor has been totally excised), adjuvant therapy is of uncertain benefit. Both ... Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K (February 2000). "Benefits of adjuvant ...
... surgery with adjuvant chemoradiotherapy. The chemotherapy drugs paclitaxel and carboplatin have shown a clinical (but not ... No link has been found between malignancy and initial chemoradiotherapy treatment, and the overall survival rate was very poor ... HPS stain Craniopharyngiomas are usually successfully managed with a combination of adjuvant chemotherapy and neurosurgery. ...
... 19 (2007 -2012, 619 pts) - Randomized study of Zalutumumab (anti-EGFr) as adjuvant to radiotherapy. ClinicalTrials.gov ... Registration study of chemoradiotherapy in NPC DAHANCA 15 (2003-2004, 28 pts) - Phase I-II study of Zalutumumab (anti-EGFr) as ... A randomized non-inferiority trial of hypoxia-profile guided hypoxic modification with nimorazole during radiotherapy/chemo-radiotherapy ... A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer ...
Cancer treatment now is focused on limited surgery and adjuvant chemoradiotherapy rather than radical surgery, and medical ...
MacDonald (6 September 2001). "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or ... Sakuramoto (1 November 2007). "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine". NEJM. 357 (18): ...
Adjuvant chemotherapy and radiation therapyEdit. If the tumor can be removed surgically, people may receive adjuvant ... The role of combined chemoradiotherapy in this setting is unclear. However, if the tumor tissue margins are positive, ... Both positive[71][72] and negative[11][73][74] results have been reported with adjuvant radiation therapy in this setting, and ... Adjuvant therapy followed by liver transplantation may have a role in treatment of certain unresectable cases.[70] ...
... alone or chemoradiotherapy (CRT), which hampered the comparison of the efficacy of RT alone with that of surgery combined with ... adjuvant RT. But some effort had been made to reflect the role of surgery in salivary gland tumours. Treatment may include the ...
In elderly people with newly diagnosed glioblastoma who are reasonably fit, concurrent and adjuvant chemoradiotherapy gives the ... Mason WP, Mirimanoff RO, Stupp R (2006). Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for ... December 2008). "Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas". Journal of ... "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". The New England Journal of Medicine. 352 (10): 987- ...
Evidence suggests chemoradiotherapy may increase overall survival and reduce the risk of disease recurrence compared to ... Falcetta FS, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT, Rosa DD (November 2016). "Adjuvant platinum-based chemotherapy ... Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC) (January 2010). "Reducing uncertainties about the ... Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B (December 2014). "Adjuvant ...
In glioblastoma multiforme, adjuvant chemoradiotherapy is critical in the case of a completely removed tumor, as with no other ... Adjuvant therapy, also known as adjunct therapy, and adjuvant care, is therapy that is given in addition to the primary or ... Analgesic adjuvant Chemotherapy, +Adjuvant at the US National Library of Medicine Medical Subject Headings (MeSH) Anampa, Jesus ... As a result of complications that can stem from liberal use of adjuvant therapy, the philosophy surrounding the use of adjuvant ...
De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive ... Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma PMID 27943254 ... Done Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer PMID 19588382 https://doi. ... Adjuvant antiviral therapy for recurrent respiratory papillomatosis PMID 23235619 https://doi.org/10.1002/14651858.CD005053. ...
Higher tumour grades may benefit from adjuvant treatment such as platinum-based chemotherapy. Optimal debulking is used to ... This combination approach may be substituted with chemoradiotherapy alone in some. Hysterectomy and bilateral oophorectomy is ... If nodal disease is confirmed, adjuvant radiotherapy is administered. Treatment depends on the stage of vaginal cancer. ...
Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation ... Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. „J Clin Oncol". ... Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. „N Engl J Med". 357 (18), s. 1810-1820, Nov 2007. ... Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised ...
For locally advanced rectal cancer, neoadjuvant chemoradiotherapy has become the standard treatment.[121] ... radiotherapy can be used in the neoadjuvant and adjuvant setting for some stages of rectal cancer. ... "A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer". International Journal of Biological Sciences ...
March 2013). "Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent ... The addition of another modality of treatment is referred to as adjuvant (literally helping) therapy, compared to its use as ... The adequacy of surgical resection is a major factor in determining the role of postoperative adjuvant therapy. In the presence ... Such patient selection may enable them to avoid the morbidity of additional adjuvant treatment. In the absence of favourable ...
Adjuvant chemotherapy refers to the use of chemotherapy after apparently curative surgery to improve the outcome. In NSCLC, ... O'Rourke N, Roqué I, Figuls M, Farré Bernadó N, Macbeth F (June 2010). "Concurrent chemoradiotherapy in non-small cell lung ... Adjuvant chemotherapy for people with stage IB cancer is controversial, as clinical trials have not clearly demonstrated a ... June 2015). "Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta ...
"Adjuvant docetaxel/Cyclophosphamide in breast cancer patients over the age of 70: Results of an observational study". Critical ... "Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer with High-Dose Radiation and Oxaliplatin-Containing ... "Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: Results of an observational study". Critical ...
For people who have undergone curative surgery or adjuvant therapy (or both) to treat non-metastatic colorectal cancer, intense ... For locally advanced rectal cancer, neoadjuvant chemoradiotherapy has become the standard treatment. Additionally, when surgery ... 2016). "A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer". International Journal of Biological ... chemoradiotherapy can increase acute treatment-related toxicity, and has not been shown to improve survival rates compared to ...
Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K. Benefits of adjuvant radiotherapy after ... Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar ... Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T. Is postoperative adjuvant chemotherapy ... The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. Best Practice & Research Clinical Gastroenterology. ...
"Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial". ... relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy". Clinical Cancer ...
After surgery, adjuvant chemotherapy with gemcitabine or 5-FU can be offered if the person is sufficiently fit, after a ... neoadjuvant chemotherapy or chemoradiotherapy may be used in cases that are considered to be "borderline resectable" (see ... The role of radiotherapy as an auxiliary (adjuvant) treatment after potentially curative surgery has been controversial since ... there is a continuing tendency for clinicians in the US to be more ready to use adjuvant radiotherapy than those in Europe. ...
... incomplete Freund's adjuvant - indinavir - indium In 111 ibritumomab tiuxetan - indium In 111 pentetreotide - indole-3-carbinol ... chemoradiotherapy - chemosensitivity - chemosensitivity assay - chemosensitizer - chemotherapeutic agent - chemotherapy - ... uvula vaccine adjuvant - vaccine therapy - vaccinia CEA vaccine - vaginal cancer - vaginal melanoma-vaginal tumors - ... adjuvant therapy - adrenocortical - Adriamycin - adult T-cell leukemia/lymphoma - AE-941 - AEE788 - aerobic metabolism - ...
"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a ... "Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas". Journal of Neuro-Oncology. 90 ( ...
若病人的情況許可,可在手術後一段時間給予吉西他濱或5-FU等藥物進行輔助性化療(英語:Adjuvant therapy),通常輔助性化療會在術後一至兩個月實施[4][55]。對於身體情況不允許進行治癒性手
Whilst, evidence is uncertain on whether there are long term neurocognitive side effects associated with chemoradiotherapy. ... 10 March 2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". New England Journal of Medicine. ...
In locally advanced adenocarcinoma of middle and lower rectum, regional hyperthermia added to chemoradiotherapy achieved good ... Hyperthermia is usually applied as an adjuvant to radiotherapy or chemotherapy, to which it works as a sensitizer, in an effort ...
"Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer". The Cochrane Database of ... as would be expected with the concurrent chemoradiotherapy, which is the current gold standard treatment for advanced head and ... interpretation is difficult since cetuximab-radiotherapy was not directly compared to chemoradiotherapy. The results of ongoing ...
Sakuramoto (1 November 2007). "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine". NEJM. 357: 1810-20 ... MacDonald (6 September 2001). "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or ...
... such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB ... adjuvant CRT may improve the LRFS and RFS and subsequently improve OS in lymph node-positive resected GB cancer. ... cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n = 59, 39.1%) or CTx (n ... Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma. *Tae Hyun Kim. ORCID: orcid.org/0000-0001-8413-33851. ...
Concurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and standard therapy in recent ... Chemoradiotherapy* / adverse effects. Chemotherapy, Adjuvant. Cisplatin / adverse effects, therapeutic use. Diarrhea / ... CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and ... This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment ...
Three trials compared adjuvant chemoradiotherapy with adjuvant chemotherapy, and 4 trials compared adjuvant chemotherapy with ... Using indirect comparison, the relative hazards of adjuvant chemoradiotherapy to observation were 0.43 (95% CI: 0.33-0.55) in ... and performed indirect comparison to obtain the relative hazards of adjuvant chemoradiotherapy to observation on overall and ... Molecular biomarker might be a promising direction in the prediction of clinical outcome to postoperative chemoradiotherapy, ...
Radiation: Neoadjuvant Chemoradiotherapy Drug: Neoadjuvant Chemotherapy Procedure: R0 D2 Gastrectomy Drug: Adjuvant ... Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer ( ... Drug: Adjuvant Chemotherapy 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/ ... Drug: Adjuvant Chemotherapy 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/ ...
Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 - ... Response rate (by contrast CT scan) [ Time Frame: 12 weeks after completion of adjuvant chemotherapy or within 4 weeks after ... Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by ... Phase II Study of Concurrent Chemoradiotherapy Using IMRT (With Single Photon Emission Computed Tomography/SPECT-CT to Define ...
Adjuvant chemoradiotherapy: Within 16-28 days after the first vaccination, patients receive fluorouracil (5-FU) IV continuously ... PURPOSE: This phase II trial is studying how well giving vaccine therapy together with adjuvant chemoradiotherapy works in ... Disease-free Survival in Patients Treated With Adjuvant Chemoradiotherapy in Sequence With the Irradiated Allogeneic GM-CSF ... Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma ...
Brian C. Baumann, MD, on Bladder Cancer: Trial Results on Adjuvant Chemoradiotherapy vs Adjuvant Radiotherapy Alone 2019 ... discusses phase III study findings on adjuvant sequential chemotherapy plus radiotherapy vs adjuvant radiotherapy alone for ... Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin Stefanie C. Fischer, MD, of ... Ten-Year Outcomes With Neoadjuvant Chemoradiotherapy Plus Surgery vs Surgery Alone for Esophageal Cancer. View More ...
Adjuvant Chemoradiotherapy vs Radiotherapy in High-Risk Endometrial Cancer. By Matthew Stenger. Posted: 2/28/2018 11:02:40 AM. ... the phase III PORTEC-3 trial has shown no significant improvement in 5-year overall survival with adjuvant chemoradiotherapy vs ... Chemoradiotherapy did not significantly improve 5-year overall survival but did improve 5-year failure-free survival. ... The investigators concluded, "Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did ...
... Lisa Astor ... neoadjuvant chemoradiotherapy achieved a median OS of 17.1 months compared with 13.7 months with immediate surgery and adjuvant ... Median DFS was 9.9 months with neoadjuvant chemotherapy and radiation therapy versus 7.9 months with surgery and adjuvant ... Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1 ...
Adjuvant Chemoradiotherapy Superior to Radiotherapy Alone in Women With High-Risk Endometrial Cancer. ... The use of chemoradiotherapy should be recommended for women with high-risk endometrial cancer given the improved overall ... The 5-year rate of overall survival was 81.4% in the chemoradiotherapy group and 76.1% in the radiotherapy-alone group. ... This post hoc survival analysis of a phase III trial was designed to compare outcomes following treatment with adjuvant ...
Chemoradiotherapy (CRT), either given before surgical resection as neoadjuvant therapy or after resection as adjuvant therapy, ... Role of chemoradiotherapy in oesophageal cancer -- adjuvant and neoadjuvant therapy.. @article{Gwynne2014RoleOC, title={Role of ... Chemoradiotherapy (CRT), either given before surgical resection as neoadjuvant therapy or after resection as adjuvant therapy, ... Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis. *Dong-bin Wang, ...
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized ... Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized ... Objective To assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in ...
"Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a ... received adjuvant CRT. Factors associated with advantage, postoperative chemoradiotherapy (CRT) has adjuvant CRT included age ... received adjuvant CRT. Factors associated with advantage, postoperative chemoradiotherapy (CRT) has adjuvant CRT included age ... Benefit of adjuvant chemoradiotherapy for gastric adenocarcinoma: a SEER population analysis. Seyedin, S; Wang, PC; Zhang, Q; ...
... Academic Article ... Concurrent chemoradiation using capecitabine as a radiosensitizer in the adjuvant setting for pancreatic cancer was completed ...
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NAC-CCRT) is an alternative strategy for decreasing tumor ... Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) is currently recommended as the standard treatment for ... Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant ... Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) is currently recommended as the standard treatment for ...
A retrospective study of chemoradiotherapy (CRT) versus chemotherapy (CT) as adjuvant treatment for localized gastric cancer ( ... CT appears to be equally effective and less toxic than CRT as adjuvant treatment for LGC and may be a reasonable option for ... Treatment of LGC consists of surgical resection followed by adjuvant treatment. Indeed either CRT or CT regimen have shown ...
Results of this study will demonstrate whether the combination of preoperative chemotherapy and postoperative chemoradiotherapy ... From: Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with ...
... Sei Kyung Chang, Jong Woo Kim, Doyeun Oh, So Young Chong, Hyun Soo ... Postoperative Adjuvant Chemoradiotherapy in Rectal Cancer Sei Kyung Chang, Jong Woo Kim, Doyeun Oh, So Young Chong, Hyun Soo ... Postoperative adjuvant chemoradiotherapy was an effective modality for locoregional control of rectal cancer. But further ... To evaluate the role of postoperative adjuvant chemoradiotherapy in rectal cancer, we retrospectively analyzed the treatment ...
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of ... Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of ... Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of ... Background: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic ...
Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy Eirini Pectasides 1 , ... Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy Eirini Pectasides et al. ... To improve patient selection for adjuvant chemoradiotherapy, we evaluated the prognostic significance of immunohistochemical ... KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced ...
... Posted January 21, 2015. by Action ... Postoperative chemoradiotherapy may be associated with improved OS among patients with Merkel cell carcinoma, suggesting the ...
Adjuvant chemotherapy using agents other than S-1. * Neoadjuvant chemoradiotherapy. * Adjuvant chemoradiotherapy ... 6.5 Adjuvant chemotherapy using agents other than S-1. In the West, both postoperative adjuvant chemoradiation [22] and ... 6.7 Adjuvant chemoradiation therapy. Adjuvant chemoradiation therapy has become the standard in the United States since the ... 5 Adjuvant chemotherapy. Adjuvant chemotherapy is delivered with the intention to reduce recurrence by controlling residual ...
The aim of this study was to determine whether adjuvant therapy was associated with improved survival for... ... Background There are limited data on the efficacy of adjuvant therapy in ampullary cancer. ... 2 Changes in the utilization of adjuvant therapy from 2004 to 2013. ACRT = adjuvant chemoradiotherapy; ACT = adjuvant ... Survival benefit of adjuvant chemoradiotherapy in patients with ampulla of Vater cancer. Ann Surg. 2015;262:47-52.CrossRef ...
In oesophageal cancer (OC) neo‐adjuvant chemoradiotherapy (neoCRT) is used to debulk tumour size prior to surgery, with a ... Complete pathological response; FTIR spectroscopy; Machine learning; Neo-adjuvant chemoradiotherapy; Raman spectroscopy. ... Prediction of pathological response to neo‐adjuvant chemoradiotherapy for oesophageal cancer using vibrational spectroscopy. ... Prediction of pathological response to neo‐adjuvant chemoradiotherapy for oesophageal cancer using vibrational spectroscopy. ...
Timing of the consult (e.g., pre-operative/pre-treatment; immediate postoperative; during recovery; during adjuvant (chemo) ... obtaining a detailed description of the individuals current function and needs, based on the surgical resection or (chemo)radiotherapy ... Functional outcomes and quality of life after chemoradiotherapy: Baseline and 3 and 6 months post-treatment. Dysphagia, 29, 365 ... Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: Use it or lose it. JAMA Otolaryngology-Head ...
RT, radiotherapy; NAC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy; CCRT, concurrent chemo‐radiotherapy; CT, ...
Chemoradiotherapy, Adjuvant * Chemotherapy, Adjuvant * Humans * Immunotherapy / adverse effects * Immunotherapy / methods* * ...
Experimental: Concurrent and adjuvant Concurrent chemoradiotherapy plus adjuvant chemotherapy. Drug: Cisplatin,fluorouracil ... Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with ... The purpose of this study is to compare concurrent chemoradiotherapy plus adjuvant chemotherapy with concurrent ... A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent ...
Adjuvant therapy with traditional chemoradiotherapy. DHA has been shown to potentiate the pro-apoptotic properties of 5- ... Adjuvant treatment with docosahexaenoic acid may improve breast cancer survival and/or reduce cancer-related cachexia. ... both as neoadjuvant/adjuvant treatment in patients undergoing surgery with curative intent and in the management of incurable ...
Adjuvant therapy. Among the 52 individuals treated with adjuvant chemoradiotherapy, 40 completed treatment (76.9%). Regarding ... The role of adjuvant chemoradiotherapy in survival outcomes. In order to identify a specific group of patients who would ... Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a ... Patients who received adjuvant chemoradiotherapy had 5-year overall survival of 70.9% and disease-free survival of 59.1%. They ...
  • Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer. (biomedsearch.com)
  • This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment compliance of the patients with advanced cervical squamous cell carcinoma. (biomedsearch.com)
  • CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and long-term survival and local control rates of patients, improve the quality of life, and the toxicity can be tolerated. (biomedsearch.com)
  • The purpose of this study is to compare concurrent chemoradiotherapy plus adjuvant chemotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced NPC, in order to evaluate the value of adjuvant chemotherapy in nasopharyngeal carcinoma (NPC) patients. (clinicaltrials.gov)
  • Patients presented with non-keratinizing NPC and stage T3-4N1M0/TxN2-3M0 are randomly assigned to receive concurrent chemoradiotherapy plus adjuvant chemotherapy (investigational arm)or concurrent chemoradiotherapy (control arm). (clinicaltrials.gov)
  • Therefore, further clinical studies to assess the role and compare the effectiveness of different adjuvant modalities in GB cancer patients who have received surgical resection should be needed even with retrospective studies. (nature.com)
  • The high rate of relapse or distant metastases after resection make it important to consider adjuvant treatment for patients with resected gastric cancer. (hindawi.com)
  • Chemoradiotherapy (CRT), either given before surgical resection as neoadjuvant therapy or after resection as adjuvant therapy, has been postulated to improve these outcomes. (semanticscholar.org)
  • Treatment of LGC consists of surgical resection followed by adjuvant treatment. (esmo.org)
  • To evaluate the role of postoperative adjuvant chemoradiotherapy in rectal cancer, we retrospectively analyzed the treatment outcome of patients with rectal cancer taken curative surgical resection and postoperative adjuvant chemoradiotherapy. (e-roj.org)
  • A total 46 patients with AJCC stage II and III carcinoma of rectum were treated with curative surgical resection and postoperative adjuvant chemoradiotherapy. (e-roj.org)
  • Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. (springer.com)
  • The Intergroup US 0116 Trial (INT 0116)[ 7 ] demonstrated survival improvement with the addition of chemoradiotherapy after negative-margin resection of tumors without distant metastases. (springer.com)
  • IMPORTANCE Distant recurrence following preoperative chemoradiotherapy and resection in patients with gastroesophageal adenocarcinoma is common. (elsevier.com)
  • OBJECTIVE To compare adjuvant chemotherapy with postoperative observation following preoperative chemoradiotherapy and resection in patients with gastroesophageal adenocarcinoma. (elsevier.com)
  • DESIGN, SETTING, AND PARTICIPANTS Propensity score-matched analysis using the National Cancer Database.We included adult patients who received a diagnosis between 2006 and 2013 of clinical stage T1N1-3M0 or T2-4N0-3M0 adenocarcinoma of the distal esophagus or gastric cardia who were treated with preoperative chemoradiotherapy and curative-intent resection. (elsevier.com)
  • CONCLUSIONS AND RELEVANCE For patients with locally advanced gastroesophageal adenocarcinoma treated with preoperative chemoradiotherapy and resection, adjuvant chemotherapy was associated with improved overall survival. (elsevier.com)
  • For Stage II/III rectal cancer patients, curative resection is the primary treatment, prescribing of postoperative adjuvant chemotherapy (PAC) is regarded as a standard therapy. (scirp.org)
  • After surgical resection of pancreatic cancer, patients who received chemotherapy have fewer distant disease recurrences and longer overall survival than those who also had adjuvant chemoradiation therapy. (medindia.net)
  • Dr. Parikh noted that this study is the first to examine the relationship between adjuvant chemotherapy and chemotherapy plus radiation on the patterns of disease recurrence and overall survival after primary surgical resection of pancreatic cancer. (medindia.net)
  • In a plenary presentation in the Navigating Uncertain Times in Muscle-Invasive and Advanced Bladder Cancer session at the 2021 ASCO GU Cancers Symposium, Dr. Dean Bajorin presents the results of CheckMate-274 assessing the role of adjuvant nivolumab in patients following radical resection with or without NAC with cisplatin. (urotoday.com)
  • We investigated the role of adjuvant concurrent chemoradiation therapy (CCRT) in patients with a microscopically positive resection margin (R1) after curative resection for extrahepatic cholangiocarcinoma (EHCC). (springer.com)
  • Fifty-two patients with negative resection margins did not receive any adjuvant treatments (R0 + S group). (springer.com)
  • The remaining 32 patients with microscopically positive resection margins received either adjuvant CCRT (R1 + CCRT group, n = 19) or adjuvant radiation therapy (RT) alone (R1 + RT group, n = 13). (springer.com)
  • A lack of significant survival difference between R0 + S group and R1 + CCRT group suggests that adjuvant CCRT ameliorates the negative effect of microscopic positive resection margin. (springer.com)
  • Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. (springer.com)
  • A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. (remedium.ru)
  • Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. (remedium.ru)
  • En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. (remedium.ru)
  • A transthoracic en-bloc esophagectomy with radical lymphadenectomy should be the best surgical option to achieve complete resection. (eur.nl)
  • But, these preliminary results of PREOPANC suggest a benefit of preoperative chemoradiotherapy over immediate surgery followed by adjuvant chemotherapy," said lead study author Geertjan Van Tienhoven, MD, PhD, of the Department of Radiation Oncology, Academic Medical Center in Amsterdam, Netherlands. (onclive.com)
  • Postoperative pathologic stage is one of the most important prognostic factors in patients with rectal cancer after surgery and preoperative chemoradiotherapy (CRT). (2minutemedicine.com)
  • In this multicenter, randomized, controlled trial, 321 patients with postoperative ypStage II (ypT3-4N0) or III (ypT any N1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and total mesorectal excision (TME) were randomized to receive adjuvant chemotherapy with either fluorouracil and leucovorin (FL) or FOLFOX (oxaliplatin, leucovorin, and fluorouracil) to study disease-free survival (DFS). (2minutemedicine.com)
  • Overall, this study suggests that adjuvant FOLFOX may improve disease-free survival in patients with postoperative ypStage II or III rectal cancer who received preoperative CRT and TME, but is associated with a higher rate of adverse events. (2minutemedicine.com)
  • Preoperative chemoradiotherapy (CRT) has been used as a standard treatment in patients with locally advanced rectal cancer (LARC) because of increased local control, organ preservation and less toxicity [ 1 ]. (jcancer.org)
  • First, in the absence of reliable preoperative imaging, a 10th of patients who were initially diagnosed with locally advanced rectal cancer might have had unnecessary chemoradiotherapy, as shown in the German study (7). (deepdyve.com)
  • Secondly, although preoperative chemoradiotherapy has shown to increase sphinter saving surgeries (7), this may only apply to a specific subgroup of patients, as sphinter saving surgery may be unnecessary and sometimes unavoidable even with chemoradiotherapy. (deepdyve.com)
  • In addition to that, the toxicity profile superiority of preoperative chemoradiotherapy may be controversial, as one large American study has shown (9). (deepdyve.com)
  • Lastly, the superiority in survival outcome of preoperative chemoradiotherapy has not been shown in two major randomized controlled trials (7,9). (deepdyve.com)
  • Preoperative concurrent chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancers. (oncolink.org)
  • The current study tested the hypothesis that the clinical outcome of patients with localized esophageal carcinoma after preoperative chemoradiotherapy (CTRT) depends on histology. (wiley.com)
  • However, the role of adjuvant treatments and optimal treatment modalities remains controversial. (nature.com)
  • This multicenter study evaluated the outcomes and role of adjuvant treatment in patients with stage I to II OCSCC. (nih.gov)
  • The role of adjuvant chemoradiation, however, is often used at the discretion of the treating physician, and is usually recommended for patients who have signs of local disease advancement, such as positive lymph nodes or positive surgical margins. (medindia.net)
  • Further, the role of adjuvant chemotherapy is unclear in patients who have residual disease following NAC. (urotoday.com)
  • Three trials compared adjuvant chemoradiotherapy with adjuvant chemotherapy, and 4 trials compared adjuvant chemotherapy with observation. (hindawi.com)
  • Little data on directly comparing chemoradiotherapy with observation has yet been published in the setting of adjuvant therapy for resected gastric cancer who underwent D2 lymphadenectomy. (hindawi.com)
  • Using indirect comparison, the relative hazards of adjuvant chemoradiotherapy to observation were 0.43 (95% CI: 0.33-0.55) in disease-free survival and 0.52 (95% CI: 0.38-0.71) in overall survival for completely resected gastric cancer with D2 lymphadenectomy. (hindawi.com)
  • Postoperative chemoradiotherapy can prolong survival and decrease recurrence in patients with resected gastric cancer who underwent D2 gastrectomy. (hindawi.com)
  • There is no RCT comparing adjuvant chemoradiotherapy with observation D2-dissected gastric cancer. (hindawi.com)
  • All RCTs that compared chemotherapy with observation or compared chemoradiotherapy with chemotherapy in adjuvant therapy for resected gastric cancer were included in the present study. (hindawi.com)
  • Patients with histologically confirmed gastric adenocarcinoma with locally advanced gastric cancer are randomized in a 1:1 ratio to receive neoadjuvant chemoradiotherapy with DT45Gy/25f plus three cycles of XELOX therapy or neoadjuvant chemotherapy alone using XELOX regimen following D2 gastrectomy and adjuvant chemotherapy for 3 cycles. (clinicaltrials.gov)
  • Background: Literatures have shown that patitents with locally advanced gastric cancer could potentially benefit from neoadjuvant chemoradiotherapy, but whether this can improve patitents' outcome is still unclear. (clinicaltrials.gov)
  • Jennifer M. Yeh Angela C. Tramontano Chin Hur Deborah Schrag Received: 22 December 2016 / Accepted: 14 January 2017 / Published online: 15 February 2017 The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2017 Abstract Results Of the 1519 patients who underwent gastrectomy, Background Since the INT-0116 trial reported a survival 41.7% received adjuvant CRT. (deepdyve.com)
  • Factors associated with advantage, postoperative chemoradiotherapy (CRT) has adjuvant CRT included age younger than 75 years at can- been a care standard for US patients in whom gastric cer diagnosis and stage II or stage III cancer. (deepdyve.com)
  • Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. (springer.com)
  • Adjuvant chemoradiotherapy is part of a multimodality treatment approach in order to improve survival outcomes after surgery for gastric cancer. (springer.com)
  • N-category and N-ratio interaction, perineural invasion and extended resections were prognostic factors for survival in gastric cancer patients treated with D2-lymphadenectomy, but adjuvant chemoradiotherapy was not. (springer.com)
  • The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. (cancer.org)
  • We conducted a systematic review of randomized controlled trials, extracted time-to-event data using Tierney methods (when not reported), and performed indirect comparison to obtain the relative hazards of adjuvant chemoradiotherapy to observation on overall and disease-free survival. (hindawi.com)
  • Determine overall and disease-free survival of patients with resected stage I or II adenocarcinoma of the pancreas treated with adjuvant chemoradiotherapy in combination with GVAX pancreatic cancer vaccine. (clinicaltrials.gov)
  • Objective To assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in patients with HNSCC. (eur.nl)
  • Sixty-six patients experienced neutropenia at least once during concurrent chemoradiotherapy , and demonstrated marginal improvement in disease-free survival (p=0.055), although not in overall survival . (bvsalud.org)
  • The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sen. (bioportfolio.com)
  • Of these, 98 (64.9%) patients received adjuvant therapy with CTx (n = 39, 25.8%) or CRT (n = 59, 39.1%), and the remaining 53 (35.1%) did not (no adjuvant therapy [No-AT]) (Table 1 ). (nature.com)
  • BACKGROUND AND OBJECTIVE: Concurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and standard therapy in recent years. (biomedsearch.com)
  • Ten days after radiation therapy, TP regimen was administered as adjuvant chemotherapy. (biomedsearch.com)
  • Oxaliplatin 130mg/m2 on day 1 for a 21-day cycle) or neoadjuvant chemotherapy alone using XELOX regimen following by D2 gastrectomy and adjuvant chemotherapy with same dosage of XELOX therapy for up to 3 cycles. (clinicaltrials.gov)
  • Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. (clinicaltrials.gov)
  • Previous studies have suggested the potential for neoadjuvant therapy instead of adjuvant therapy in pancreatic cancer, yet most of these data were from observational studies, Van Tienhoven commented. (onclive.com)
  • Although Van Tienhoven noted that the OS rate was just not statistically significant with a P value of .074, he pointed to the 2-year OS rate of 42% with neoadjuvant therapy, which compared favorably with the 2-year OS rate of 30% from surgery and adjuvant chemotherapy. (onclive.com)
  • Role of chemoradiotherapy in oesophageal cancer -- adjuvant and neoadjuvant therapy. (semanticscholar.org)
  • There are limited data on the efficacy of adjuvant therapy in ampullary cancer. (springer.com)
  • The aim of this study was to determine whether adjuvant therapy was associated with improved survival for patients with ampullary cancer. (springer.com)
  • In this retrospective study, the use of adjuvant therapy in ampullary cancer was associated with significantly improved overall survival. (springer.com)
  • The benefit of adjuvant therapy for this disease should be confirmed in a more rigorous fashion via randomized controlled trials. (springer.com)
  • Supplementary Fig. 2 Changes in the utilization of adjuvant therapy from 2004 to 2013. (springer.com)
  • Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. (springer.com)
  • Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. (springer.com)
  • Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. (springer.com)
  • Giving chemotherapy (chemo), either alone or with radiation therapy (chemoradiation), after surgery (known as adjuvant treatment ) might help some patients live longer. (cancer.org)
  • Radiotherapy after surgery is called adjuvant therapy. (cancerresearchuk.org)
  • Adjuvant aromatase inhibitor therapy: Patients receive oral letrozole daily for up to 5 years in the absence of disease progression or unacceptable toxicity. (bioportfolio.com)
  • Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors. (bioportfolio.com)
  • Adjuvant radiation therapy (RT) for breast cancer is associated with heart disease, although the impact of patient-specific factors on the interaction between cardiac risk and RT is not well-studied i. (bioportfolio.com)
  • Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women. (bioportfolio.com)
  • The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the comparison of zoledronate added to standard adjuvant therapy with controls according to diseas. (bioportfolio.com)
  • Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy. (bioportfolio.com)
  • It is now increasingly common for breast cancer patients to receive adjuvant tamoxifen therapy for a period of up to 10 years. (bioportfolio.com)
  • 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. (bioportfolio.com)
  • In the phase III GOG 258 trial reported in The New England Journal of Medicine, Matei et al found that 6 months of adjuvant platinum-based chemotherapy plus radiation therapy did not improve relapse-free survival vs chemotherapy alone in stage III or IVA endometrial cancer. (ascopost.com)
  • FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. (medscape.com)
  • Significant leaks may result in re-operation with the potential for permanent stoma formation, delayed administration of adjuvant therapy and potentially adverse oncological outcomes. (omicsonline.org)
  • Review of the published literature is difficult because of the variation in adjuvant therapy regimes and follow-up strategies, as well as results reported in terms of local recurrence and survival rates. (karger.com)
  • The place for local excision in patients with T2 or high-risk T1 tumours requires prospective, randomised multi-centre trials comparing radical surgery with local excision, with or without adjuvant therapy. (karger.com)
  • This study provides preliminary evidence demonstrating the feasibility and safety of M1-tDCS as a potential adjuvant neuromechanism-driven analgesic therapy for head and neck cancer patients receiving CRT, inducing immediate and long-term changes in the cortical activity and clinical measures, with minimal side-effects. (frontiersin.org)
  • This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy. (centerwatch.com)
  • Findings from the first multicenter clinical trial to relate disease recurrence patterns to the type of adjuvant therapy indicate that patients should receive a full course of chemotherapy rather than chemoradiotherapy following surgical treatment for pancreatic cancer. (medindia.net)
  • Because of the high incidence of disease recurrence, adjuvant therapy is given routinely after surgery for pancreatic cancer. (medindia.net)
  • Adjuvant therapy typically involves systemic chemotherapy given with or without chemoradiotherapy. (medindia.net)
  • The goal here was to determine how adjuvant therapy affects disease recurrence. (medindia.net)
  • Unless we get better evidence to show that radiation helps in resected pancreatic cancer, we believe adjuvant therapy should be confined to chemotherapy after surgery," Dr. Parikh said. (medindia.net)
  • In patients who do not receive NAC for whatever reason, there is no conclusive data to support the use of adjuvant therapy. (urotoday.com)
  • Patients randomized to receive nivolumab were administered nivolumab 240mg every 2 weeks for up to 1 year of adjuvant therapy. (urotoday.com)
  • Authors: Naito T, Higuchi T, Shimada Y, Kakinuma C Abstract Nonmuscle-invasive (superficial) bladder cancer is generally treated via surgical removal, followed by adjuvant therapy (bacillus Calmette-Guerin). (medworm.com)
  • Standard therapy (chemoradiotherapy and adjuvant temozolomide): Beginning after surgery, patients receive chemoradiotherapy comprising oral temozolomide daily for 6 weeks and radiotherapy once daily, 5 days a week for 6 weeks. (knowcancer.com)
  • 2018-06-04 00:00:00 Abstract Background Intensity-modulated radiotherapy (IMRT) has yet to show its capability in the adjuvant treatment of locally advanced rectal cancer. (deepdyve.com)
  • rectal cancer, adjuvant treatment, intensity modulated radiotherapy, neutropenia Introduction Radiotherapy has been an integral part of rectal cancer treatment. (deepdyve.com)
  • As reported in The Lancet Oncology by de Boer et al, the phase III PORTEC-3 trial has shown no significant improvement in 5-year overall survival with adjuvant chemoradiotherapy vs radiotherapy alone in women with high-risk endometrial cancer. (ascopost.com)
  • This post hoc survival analysis of a phase III trial was designed to compare outcomes following treatment with adjuvant chemoradiotherapy and radiotherapy versus radiotherapy alone among women with high-risk endometrial cancer. (cancer.org)
  • The use of chemoradiotherapy should be recommended for women with high-risk endometrial cancer given the improved overall survival and failure-free survival associated with it. (cancer.org)
  • In the CTx group, a median of 6 cycles (range, 1-8) of chemotherapy with gemcitabine (n = 31, enrolled in the Phase II adjuvant trial [NCCTS07411]), gemcitabine and cisplatin (n = 5), capecitabine and cisplatin (n = 2), and 5-fluorouracil (5-FU) and leucovorin (n = 1), were received. (nature.com)
  • Participants were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or chemoradiotherapy (two cycles of cisplatin 50 mg/m2 given intravenously during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2 given intravenously), by use of a biased coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage, and histological type. (cancer.org)
  • Patients with node-positive disease had improved survival with adjuvant chemoradiotherapy, especially when we grouped patients with N1 and N2 tumors and a higher N-ratio. (springer.com)
  • IMA950 plus sargramostim (GM-CSF) in combination with standard chemoradiotherapy comprising temozolomide and radiotherapy followed by adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. (knowcancer.com)
  • All patients undergo standard chemoradiotherapy followed by adjuvant temozolomide as planned. (knowcancer.com)
  • Approximately 1-2 weeks after completion of 5-FU, patients receive chemoradiotherapy comprising radiotherapy daily and 5-FU IV continuously for 26-28 weeks. (clinicaltrials.gov)
  • In the open-label international trial, 660 eligible patients with high-risk disease from 103 sites in the United Kingdom, Australia, New Zealand, Italy, Canada, and France collaborating in the Gynaecological Cancer Intergroup were randomized between November 2006 and December 2013 to receive chemoradiotherapy (n = 330) or pelvic radiotherapy alone (n = 330). (ascopost.com)
  • The INT-0116 trial [ 4 , 5 ], the largest phase III trial comparing chemoradiotherapy versus observation, shows that adjuvant chemoradiotherapy prolonged overall survival (OS) and relapse-free survival (RFS). (hindawi.com)
  • Does Adjuvant Chemoradiotherapy Extend Relapse-Free Survival in Stage III or IVA Endometrial Cancer? (ascopost.com)
  • pointed out, early initiation of adjuvant chemotherapy may have a positive impact on the relapse free survival and overall survival of colorectal cancer (12). (deepdyve.com)
  • METHODS: A total of 156 patients with stage IIa-IIIb cervical squamous cell carcinoma were randomly divided into the concurrent chemoradiotherapy group (experimental group) and radiotherapy group (control group). (biomedsearch.com)
  • Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) is currently recommended as the standard treatment for locally advanced nasopharyngeal carcinoma (LA-NPC). (biomedcentral.com)
  • Postoperative chemoradiotherapy may be associated with improved OS among patients with Merkel cell carcinoma, suggesting the approach could be an important management tool for this high-risk population. (actionradiotherapy.org)
  • BACKGROUND: We aimed to investigate the association between single-nucleotide polymorphisms (SNP) in mismatch repair (MMR) pathway genes and survival in patients with oral squamous cell carcinoma (OSCC) who received adjuvant concurrent chemoradiotherapy (CCRT). (elsevier.com)
  • abstract = "BACKGROUND: We aimed to investigate the association between single-nucleotide polymorphisms (SNP) in mismatch repair (MMR) pathway genes and survival in patients with oral squamous cell carcinoma (OSCC) who received adjuvant concurrent chemoradiotherapy (CCRT).METHODS: Using the Sequenom iPLEX MassARRAY system, five SNPs in four major MMR genes were genotyped in 319 patients with OSCC who received CCRT treatment. (elsevier.com)
  • To evaluate the prognostic significance of adjuvant concurrent chemoradiotherapy -induced neutropenia with survival in patients with squamous cell carcinoma of the uterine cervix . (bvsalud.org)
  • PURPOSE: This randomized phase III trial is studying how well adjuvant tamoxifen works compared to anastrozole in treating postmenopausal women who have undergone surgery to remove ductal carcinoma in situ. (bioportfolio.com)
  • Compare the efficacy of adjuvant tamoxifen vs anastrozole, in terms of local control and prevention of contralateral disease, in postmenopausal women with locally excised ductal carcinoma in situ. (bioportfolio.com)
  • To evaluate the benefit of adjuvant treatments, such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB) cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n = 59, 39.1%) or CTx (n = 39, 25.8%), and the remaining 53 (35.1%) did not (No-AT). (nature.com)
  • two deaths in the chemoradiotherapy group and one in the radiotherapy group were due to either intercurrent disease or late treatment-related toxicity. (ascopost.com)
  • Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NAC-CCRT) is an alternative strategy for decreasing tumor size and controlling micrometastases before main treatment. (biomedcentral.com)
  • CT appears to be equally effective and less toxic than CRT as adjuvant treatment for LGC and may be a reasonable option for centers with limited access to radiotherapy. (esmo.org)
  • Adjuvant treatment with docosahexaenoic acid may improve breast cancer survival and/or reduce cancer-related cachexia. (bmj.com)
  • The aims of this study are to describe the results of gastrectomy and adjuvant chemoradiotherapy in patients treated in a single institution, and to identify prognostic factors that could determine which individuals would benefit from this treatment. (springer.com)
  • Purpose The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. (elsevier.com)
  • Conclusion Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment. (elsevier.com)
  • 0001). The multivariate analysis revealed that adjuvant treatment significantly improved the outcomes of patients with close/positive margins (P = .002 to .03). (nih.gov)
  • Patients with head and neck cancer often experience a significant decrease in their quality of life during chemoradiotherapy (CRT) due to treatment-related pain, which is frequently classified as severe. (frontiersin.org)
  • This combined treatment is known as chemoradiotherapy (or chemoradiation). (healthtalk.org)
  • The purpose of this study is to evaluate the clinical efficacy and safety profile of IMRT in the adjuvant treatment of rectal cancer. (deepdyve.com)
  • Method Consecutive patients with resected locally advanced rectal cancer who had IMRT as part of adjuvant treatment between 2008 and 2014 were identified. (deepdyve.com)
  • Conclusion Integration of IMRT in the adjuvant treatment of rectal cancer is promising with competitive local control rate. (deepdyve.com)
  • This study aimed to examine the toxicities, oncologic outcomes and interaction of radiotherapy with fluorouracil (5-Fu)-based regimen in the adjuvant treatment of locally advanced rectal cancer with IMRT. (deepdyve.com)
  • Treatment Surgery All patients had total mesorectal excision (TME) prior to chemotherapy and/or chemoradiotherapy. (deepdyve.com)
  • Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis. (cancerindex.org)
  • The aim of this study was to compare the efficacy and toxicity of different concurrent chemoradiotherapy (CCRT) regimens in the treatment of advanced cervical cancer (CC) by adopting a network meta-analysis. (cancerindex.org)
  • 3) I am a co-applicant and steering group member for PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. (ncl.ac.uk)
  • Chemoradiotherapy did not significantly improve 5-year overall survival but did improve 5-year failure-free survival. (ascopost.com)
  • Five-year overall survival was 81.8% in the chemoradiotherapy group vs 76.7% in the radiotherapy group (adjusted hazard ratio [HR] = 0.76, P = .11). (ascopost.com)
  • The investigators concluded, "Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did not improve 5-year overall survival, although it did increase failure-free survival. (ascopost.com)
  • The 5-year rate of overall survival was 81.4% in the chemoradiotherapy group and 76.1% in the radiotherapy-alone group. (cancer.org)
  • When controlling for several associated factors, adjuvant chemotherapy led to a 29 percent improvement in overall survival when compared to surgery alone while chemoradiation did not significantly improve survival. (medindia.net)
  • Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a dtudy reported to the conference in Orlando. (audiomedica.com)
  • Post chemoradiotherapy vaccination: Within 4-8 weeks after the completion of chemoradiotherapy, patients receive GVAX pancreatic cancer vaccine ID on days 0, 28, 56, and 196. (clinicaltrials.gov)
  • Currently, the standard of care for patients with resectable or borderline resectable pancreatic adenocarcinoma is surgery followed by adjuvant chemotherapy. (onclive.com)
  • Adjuvant chemotherapy with fluorouracil and leucovorin improves survival rates and should be offered to patients with resectable pancreatic cancer. (aafp.org)
  • Adjuvant chemoradiotherapy: Within 16-28 days after the first vaccination, patients receive fluorouracil (5-FU) IV continuously for 3 weeks. (clinicaltrials.gov)
  • In 2001, findings from the Southwestern Oncology Group-Intergroup Trial (INT0116) in the US demonstrated that adjuvant chemoradiotherapy (CRT) with fluorouracil and leucovorin plus external-beam radiation was associated with improved OS compared to surgery-only ( 7 ). (amegroups.com)
  • Adjuvant fluorouracil-based chemotherapy may prolong survival. (aafp.org)
  • Brian C. Baumann, MD , of Washington University School of Medicine, discusses phase III study findings on adjuvant sequential chemotherapy plus radiotherapy vs adjuvant radiotherapy alone for locally advanced bladder cancer after radical cystectomy (Abstract 351). (ascopost.com)
  • Therefore, adjuvant CRT may improve the LRFS and RFS and subsequently improve OS in lymph node-positive resected GB cancer. (nature.com)
  • Because of the low incidence of GB cancer, prospective clinical studies to investigate the role and compare the effectiveness of different adjuvant therapeutic modalities, such as CRT and CTx, for GB cancer are difficult to conduct and have rarely been performed. (nature.com)
  • The aim of the present study was to evaluate the benefit of adjuvant treatments, such as CRT and CTx, compared with that of surgery alone in resected GB cancer patients. (nature.com)
  • Postoperative adjuvant chemoradiotherapy was an effective modality for locoregional control of rectal cancer. (e-roj.org)
  • In oesophageal cancer (OC) neo‐adjuvant chemoradiotherapy (neoCRT) is used to debulk tumour size prior to surgery, with a complete pathological response (pCR) observed in approximately ∼30% of patients. (ucd.ie)
  • Adjuvant chemotherapy is also recommended after surgery for patients with postoperative pathologic stages II and III rectal cancer. (2minutemedicine.com)
  • And, although only adjuvant fluoropyrimidines have demonstrated a survival benefit, oxaliplatin-based regimens are widely used in this setting based on the extrapolation of results from patients with colon cancer. (2minutemedicine.com)
  • Concurrent chemoradiotherapy -induced neutropenia may be a prognostic factor of recurrence in patients with cervical cancer . (bvsalud.org)
  • Our study highlights that the application of a multimodal regimen to patients affected by rectal cancer , based on neo-adjuvant chemotherapy and radiotherapy followed by surgery after 5-10 weeks (TME) is not connected to a higher risk of early complications, and in particular does not cause any statistically significant increase in anastomotic dehiscence. (biomedcentral.com)
  • Neoadjuvant chemoradiotherapy is not currently a standard option for patients with biliary tract cancer. (medscape.com)
  • Neuhaus P, Riess H, Post S. CONKO-001:Final results of the randomized, prospective multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancratic cancer. (medscape.com)
  • Adjuvant platinum-based chemoradiation should be considered after surgery for women with early cervical cancer (stage IA2-IIA) and risk factors for recurrence because it has been shown to reduce mortality. (aafp.org)
  • To meet these demands, clinical experiences on the adjuvant IMRT on locally advanced rectal cancer is urgently needed. (deepdyve.com)
  • Material and method Patient selection Seventy-two patients with rectal cancer treated with adjuvant IMRT were identified at our department. (deepdyve.com)
  • This phase I trial studies how well atezolizumab before and / or with standard of care chemoradiotherapy works in immune system activation in patients with stage IB2, II, IIIB, or IVA cervical cancer that has spread to the lymph nodes. (cancer.gov)
  • The landmark Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study (CROSS) trial has become preferred in locally advanced esophageal cancer. (dovepress.com)
  • Because of the uneliminable effects in improving resectability, long-term outcome and life quality [ 3 - 5 ], neoadjuvant chemoradiotherapy (NACRT) plus surgery followed by adjuvant chemotherapy (ACT) or not is recommended by the National Comprehensive Cancer Network (NCCN) as the standard mode to manage locoregionally advanced rectal cancer (LARC) [ 6 ]. (jcancer.org)
  • He was operated four years ago because of colon cancer and he received adjuvant chemoradiotherapy. (bioline.org.br)
  • Molecular biomarker might be a promising direction in the prediction of clinical outcome to postoperative chemoradiotherapy, which warranted further study. (hindawi.com)
  • concurrent chemoradiotherapy cycle nadir, correlated to the pathologic findings and survival outcomes. (bvsalud.org)
  • The researchers assessed the patterns of disease recurrence in three groups of patients: those who underwent a surgical procedure alone, those who had adjuvant chemotherapy, and those who had radiotherapy in addition to chemotherapy. (medindia.net)
  • This is a retrospective multicenter study including all patients who underwent en-bloc esophagectomy for esophageal sarcoma in seven European tertiary referral centers between 1987 and 2016. (eur.nl)
  • Adjuvant chemotherapy was associated with a survival benefit compared with postoperative observation in most patient subgroups. (elsevier.com)
  • however, a later study investigating chemoradiotherapy with 5-FU did not show a survival benefit. (medscape.com)
  • The benefit of adjuvant chemotherapy after neoadjuvant chemoradiotherapy followed by surgery is unknown. (centerwatch.com)
  • Such patients stand to benefit most from adjuvant or primary chemoradiotherapy, thus avoiding surgery altogether. (cmaj.ca)
  • Materials and Methods A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively. (elsevier.com)
  • Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period. (elsevier.com)
  • CONCLUSIONS: Our results indicated that the GG genotypes of MSH2 rs3732183 and MLH1 rs1800734 are associated with relatively high survival in OSCC patients treated using adjuvant CCRT. (elsevier.com)
  • The aim of the study was to examine pretreatment NLR and PLR to select from radical surgery or definitive chemoradiotherapy (dCRT) for these patients. (dovepress.com)
  • Two retrospective studies demonstrated that adjuvant chemoradiotherapy was well tolerated with acceptable toxicities and reasonable tumor control for patients with D2 gastrectomy [ 6 , 7 ]. (hindawi.com)